Welcome to the pfizer inflammation & immunology pipeline
select a hexagon to explore trials by therapeutic area





DISEASE
STATE
DERMATOLOGY1,a
PHASE 1
PHASE 2


INHIBITOR
MORE INFO COMING SOON
PHASE 3


INHIBITOR
RECRUITING


INHIBITOR
RECRUITING
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY DERMATOLOGY COMPOUNDS 1,a
Crisaborole

Inhibitor
Dermatology disease states under investigation:6,7
Atopic dermatitis and stasis dermatitis
Abrocitinib (PF-04965842)

Inhibitor
Dermatology disease states under investigation:8,9
Atopic dermatitis
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS
Crisaborole is a topical PDE4 inhibitor under
investigation for once daily
use in atopic dermatitis
LEARN MORE ABOUT OUR OTHER ONGOING TRIALS
Brepocitinib is an investigational topical
TYK2/JAK1 inhibitor for plaque
psoriasis





DISEASE
STATE
GASTROENTEROLOGY1,a
PHASE 1


INHIBITOR
COMPLETED
PHASE 2


DGAT2
INHIBITOR
COMPLETED


INHIBITOR
COMPLETED


INHIBITOR
RECRUITING
PHASE 3
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY GASTROENTEROLOGY COMPOUNDS1,a
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
Brepocitinib is an investigational oral
TYK2/JAK1 inhibitor and ritlecitinib is an
investigational oral JAK3/TEC inhibitor for
ulcerative colitis





DISEASE
STATE
RHEUMATOLOGY1,a
PHASE 1


INHIBITOR
RECRUITING
PHASE 2
PHASE 3


JAK3
INHIBITOR
RECRUITING


JAK3d
INHIBITOR
RECRUITING
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY RHEUMATOLOGY COMPOUNDS1,a
Tofacitinib

JAK3
Inhibitor
Rheumatology disease states under investigation:2,3
Juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS
Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for systemic juvenile idiopathic arthritis
Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for juvenile idiopathic arthritis
LEARN MORE ABOUT OUR OTHER ONGOING TRIALS
Dermatology
Over 5 compounds under investigation in multiple dermatology disease statesalopecia areata
VITILIGO
atopic dermatitis
plaque psoriasis
STASIS DERMATITIS
HIDRADENITIS SUPPURATIVA

JAK1b,c
INHIBITOR

TEC
INHIBITOR

JAK1c
INHIBITOR

JAK1f
INHIBITOR

INHIBITOR

JAK1f
INHIBITOR

INHIBITOR

INHIBITOR

INHIBITOR

JAK1c
INHIBITOR

TECd,e
INHIBITOR

INHIBITOR

INHIBITOR
Gastroenterology
Over 4 compounds under investigation in multiple gastroenterology disease statescrohn's disease
ulcerative colitis
NAFLD/NASHi

INHIBITOR

TEC
INHIBITOR

JAK1c
INHIBITOR

IMMUNO-
CYTOKINE

BLOCKER

INHIBITOR

TEC
INHIBITOR

JAK1c
INHIBITOR

DGAT2
INHIBITOR

INHIBITOR

INHIBITOR
Rheumatology
Over 6 compounds under investigation in multiple rheumatology disease statesLupus
PSORIATIC ARTHRITIS
Rheumatoid arthritis
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
JUVENILE IDIOPATHIC ARTHRITIS

INHIBITOR

BLOCKER

JAK1c
INHIBITOR

JAK1c
INHIBITOR

IMMUNO-
CYTOKINE

INHIBITOR

TEC
INHIBITOR

JAK3
INHIBITOR

JAK3l
INHIBITOR